Claretta sells REGN 304.51: EYLEA® (aflibercept) Injection Receives FDA Approval For The Treatment Of Diabetic Macular Edema (DME)
TARRYTOWN, N.Y., July 29, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has approved EYLEA ® (aflibercept) Injection for the treatment of Diabetic Macular Edema (DME). ...
37 people liked this
0 Comments:
Post a Comment
Subscribe to Post Comments [Atom]
<< Home